MA31259B1 - Formes solides d'un inhibiteur des kinases raf - Google Patents

Formes solides d'un inhibiteur des kinases raf

Info

Publication number
MA31259B1
MA31259B1 MA32229A MA32229A MA31259B1 MA 31259 B1 MA31259 B1 MA 31259B1 MA 32229 A MA32229 A MA 32229A MA 32229 A MA32229 A MA 32229A MA 31259 B1 MA31259 B1 MA 31259B1
Authority
MA
Morocco
Prior art keywords
inhibitor
solid forms
raf kinases
raf
kinases
Prior art date
Application number
MA32229A
Other languages
Arabic (ar)
English (en)
Inventor
Ahmad Hashash
Kangwen L Lin
Augustus O Okhamafe
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA31259B1 publication Critical patent/MA31259B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La présente invention concerne des formes solides de l'inhibiteur des kinases raf 1-méthyl-5-(2-(5-(
MA32229A 2007-03-02 2009-09-24 Formes solides d'un inhibiteur des kinases raf MA31259B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90445507P 2007-03-02 2007-03-02
PCT/US2008/055227 WO2008140850A1 (fr) 2007-03-02 2008-02-28 Formes solides d'un inhibiteur des kinases raf

Publications (1)

Publication Number Publication Date
MA31259B1 true MA31259B1 (fr) 2010-03-01

Family

ID=39456506

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32229A MA31259B1 (fr) 2007-03-02 2009-09-24 Formes solides d'un inhibiteur des kinases raf

Country Status (25)

Country Link
US (1) US8324389B2 (fr)
EP (1) EP2132198A1 (fr)
JP (1) JP2010520215A (fr)
KR (1) KR20090117833A (fr)
CN (1) CN101679372A (fr)
AR (1) AR065565A1 (fr)
AU (1) AU2008251764B2 (fr)
BR (1) BRPI0808526A2 (fr)
CA (1) CA2678335A1 (fr)
CL (1) CL2008000616A1 (fr)
CO (1) CO6230987A2 (fr)
EC (1) ECSP099673A (fr)
GT (1) GT200900237A (fr)
IL (1) IL200441A0 (fr)
MA (1) MA31259B1 (fr)
MX (1) MX2009009344A (fr)
MY (1) MY148438A (fr)
NZ (1) NZ579084A (fr)
PE (1) PE20081801A1 (fr)
RU (1) RU2483064C2 (fr)
SG (1) SG179423A1 (fr)
TN (1) TN2009000356A1 (fr)
TW (1) TW200846341A (fr)
WO (1) WO2008140850A1 (fr)
ZA (1) ZA200905618B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0811097A2 (pt) * 2007-05-23 2014-12-09 Novartis Ag Inibidores de raf para o tratamento de câncer de tireoide
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
US10098859B2 (en) 2012-09-05 2018-10-16 Amri Ssci, Llc Cocrystals of p-coumaric acid
BR112017027285A2 (pt) * 2015-06-19 2018-09-11 Syn Nat Products Entpr Llc ?cocristal, composição farmacêutica e método para o tratamento de uma doença?
WO2018146253A1 (fr) 2017-02-10 2018-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et compositions pharmaceutiques pour le traitement de cancers associés à l'activation de la voie mapk
WO2019133810A1 (fr) 2017-12-28 2019-07-04 Tract Pharmaceuticals, Inc. Systèmes de culture de cellules souches pour cellules souches épithéliales colonnaires, et leurs utilisations
RU2693004C1 (ru) * 2019-03-15 2019-07-01 Лейсан Фаридовна Минигулова Противоопухолевая композиция цисплатина с ингибитором 6-фосфоглюконатдегидрогеназы

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
WO2003082272A1 (fr) * 2002-03-29 2003-10-09 Chiron Corporation Benzazoles substitues et leur utilisation en tant qu'inhibiteurs de la kinase raf
TWI387592B (zh) * 2005-08-30 2013-03-01 Novartis Ag 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
PT2046292E (pt) * 2006-07-21 2010-04-26 Novartis Ag Formulações de éteres benzimidazolil-piridílicos
PE20130814A1 (es) 2006-08-30 2013-08-08 Novartis Ag Sales de benzimidazolil piridil eteres y formulaciones que las contienen

Also Published As

Publication number Publication date
CL2008000616A1 (es) 2008-09-12
KR20090117833A (ko) 2009-11-12
RU2483064C2 (ru) 2013-05-27
AU2008251764B2 (en) 2012-09-13
US20100209418A1 (en) 2010-08-19
GT200900237A (es) 2010-06-24
RU2009136308A (ru) 2011-04-10
EP2132198A1 (fr) 2009-12-16
BRPI0808526A2 (pt) 2014-08-19
JP2010520215A (ja) 2010-06-10
TW200846341A (en) 2008-12-01
IL200441A0 (en) 2010-04-29
CA2678335A1 (fr) 2008-11-20
WO2008140850A1 (fr) 2008-11-20
MY148438A (en) 2013-04-30
US8324389B2 (en) 2012-12-04
ECSP099673A (es) 2009-11-30
ZA200905618B (en) 2010-05-26
TN2009000356A1 (en) 2010-12-31
NZ579084A (en) 2012-04-27
SG179423A1 (en) 2012-04-27
MX2009009344A (es) 2009-09-11
CO6230987A2 (es) 2010-12-20
PE20081801A1 (es) 2009-01-08
AR065565A1 (es) 2009-06-17
AU2008251764A1 (en) 2008-11-20
CN101679372A (zh) 2010-03-24

Similar Documents

Publication Publication Date Title
IL266741A (en) Broton tyrosine kinase inhibitors
MA31259B1 (fr) Formes solides d'un inhibiteur des kinases raf
CY2015016I2 (el) Αναστολεις της κινασης τυροσινης του bruton
CL2010001608A1 (es) Compuestos derivados de 2-(3-(5-oxo-4,5-dihidro-pirazin-2-il)-fenil)-4,5-dihidro-2h-isoquinolin-1-ona y 2-(3-(5-oxo-4,5-dihidro-pirazin-2-il)-fenil)-3,4-dihidro-2h-isoquinolin-1-ona, inhibidores de quinasa; composicion farmaceutica; utiles en el tratamiento de estados patologicos inflamatorios y/o inmunes.
DK1761520T3 (da) Kinaseinhibitorer
ATE496029T1 (de) Derivate von 1-phenyl-2-pyridinylalkylenalkohole als phosphodiesteraseinhibitoren
HRP20141260T1 (xx) Spojevi i sastavi kao inhibitori kinaze proteina
EA200870409A1 (ru) Антагонисты киназы pi3
EP1954277A4 (fr) Aminopyrimidines utiles en tant qu'inhibiteurs de kinases
ZA201001513B (en) 5-(4-(Haloalkoxy) phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors
EP2307025A4 (fr) Inhibiteurs de tyrosine kinase de bruton pour le traitement de tumeurs solides
EP2079727A4 (fr) Composés inhibiteurs de kinases
EP2116543A4 (fr) Nouveau dérivé d'aminopyrimidine comme inhibiteur de plk1
MA31433B1 (fr) Inhibiteurs de la p70 s6 kinase
IL198089A0 (en) An alzheimer's disease progression inhibitor containing heterocyclic compound having specific structure
NO20080265L (no) 2-(1H-indolylsulfanyl)-arylaminderivater
MA34512B1 (fr) Formes solides amorphes du chlorhydrate de la 4-[-2-[[5-méthyl-1-(2-naphtalényl)-1h-pyrazol-3-yl]oxy]éthyl]morpholine
IL187895A0 (en) Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met
DOP2005000010A (es) Inhibidores de quinasa
EP2373636A4 (fr) Inhibiteurs de la kinase 1 dépendante des phosphoinositides (pdk1)
TR201109686T2 (tr) Olmesartan'ın Farmasötik Bileşimleri.
EA200801145A1 (ru) Спироциклические производные хиназолина в качестве ингибиторов pde7
WO2007014250A3 (fr) Inhibition de kinase d'abl
EA200801666A1 (ru) КОМБИНАЦИЯ ПРОИЗВОДНЫХ ТРИАЗИНА И ИНГИБИТОРОВ HMG-CoA РЕДУКТАЗЫ
EP1978964A4 (fr) Inhibition de la tyrosine kinase jak2